Hence, KRAS-G12C mutant cells treated with the covalent inhibitor ARS1620, which forms semi-antigenic MHC-I complexes, can be utilized as tumor-specific new antigens to evoke CTL responses against KRAS-G12C cells, thereby enhancing therapeutic efficacy. This evidence concerns the gene KRAS and neoplasm.